1257265-62-5

Basic information

• Product Name: (2R,4S)-5-biphenyl-4-yl-4-(3,5-difluoro-4-methoxybenzoylamino)-2-methylpentanoic acid ethyl ester
• Synonyms: (2R,4S)-5-biphenyl-4-yl-4-(3,5-difluoro-4-methoxybenzoylamino)-2-methylpentanoic acid ethyl ester
• CAS NO: 1257265-62-5
• Molecular Weight: 481.539
• Mol File: 1257265-62-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2R,4S)-5-biphenyl-4-yl-4-(3,5-difluoro-4-methoxybenzoylamino)-2-methylpentanoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,4S)-5-biphenyl-4-yl-4-(3,5-difluoro-4-methoxybenzoylamino)-2-methylpentanoic acid ethyl ester(1257265-62-5)
• EPA Substance Registry System: (2R,4S)-5-biphenyl-4-yl-4-(3,5-difluoro-4-methoxybenzoylamino)-2-methylpentanoic acid ethyl ester(1257265-62-5)

Safety Data

• Hazardous Substances Data: 1257265-62-5(Hazardous Substances Data)

Upstream product

• 319-60-8 3,5-difluoro-4-methoxybenzoic acid 
• 149690-12-0 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid ethyl ester hydrochloride 

Downstream Products

• 1257265-61-4 (2R,4S)-5-biphenyl-4-yl-4-(3,5-difluoro-4-hydroxybenzoylamino)-2-methylpentanoic acid 
• 1257265-63-6 (2R,4S)-5-biphenyl-4-yl-4-(3,5-difluoro-4-hydroxybenzoylamino)-2-methylpentanoic acid ethyl ester 

Relevant articles and documents

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula (I') or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.